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OBJECTIVES: Over the last 3 decades, expenditure on
medicines in the UK has increased in real terms by almost
5-fold and currently forms about 12% of all NHS expen-
diture. The MANMED (MANagement of MEDicines)
survey was designed to explore how medicines are cur-
rently managed in the NHS in England. METHODS: In
May 2001, a postal survey was sent to prescribing advis-
ers and prescribing leads in 332 Primary Care Organisa-
tions (PCO) and to chief pharmacists at 275 NHS
hospital Trusts (NHSTs). RESULTS: Sixty-six percent of
PCOs and 57% of NHSTs responded to the MANMED
survey. Most PCOs report quality of prescribing as their
top priority, followed by budget adherence at both prac-
tice and PCO levels. Prescribing advisers offer an average
of 6.6 forms of support (range: 3–9), including the review
of prescribing patterns (95% of respondents), practice
visits (95%), visits to individual GPs (92%), indicators of
prescribing performance (92%) and prescribing newslet-
ters (88%). PCOs are pursuing a wide range of pres-
cribing initiatives, covering an average of 7 different
therapeutic areas, including proton pump inhibitors
(82%), antibacterials (76%), generics (76%) and statins
(62%). National targets are the main driver for prescrib-
ing initiatives, but other key inﬂuences include inappro-
priate prescribing and clinical governance. Prescribing
incentive schemes commonly include generics targets
(81%), audits (64%) and reviews of repeat prescribing
(58%). PCO involvement with secondary care varies: one
third of PCO prescribing committees include a hospital
pharmacist, and just 7% include a hospital consultant.
However, evidence from the MANMED (NHST) survey
suggests that most PCOs are represented on their local
NHST Drug and Therapeutics committee. CONCLU-
SIONS: It would appear that while cost considerations
are important, quality is perceived as the overriding prin-
ciple on which PCO prescribing strategy is based. Multi-
faceted prescribing support is widespread and national
targets are the main factor inﬂuencing choice of thera-
peutic area for prescribing initiatives.
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OBJECTIVES: At primary care, few new drugs (ND) add
value to Spanish drug formulary. Here we deﬁne a global
strategy focused to improve the general practitioner’s
(GPs) ND prescription habit. METHODS: Our strategy
is composed by two interventions and is focused on GP.
The interventions are: Generalised Intervention (GI) and
Speciﬁc Intervention (SI). A New Drugs Evaluation Com-
mittee (NDEC) guided by an evidence-based standardised
procedure, compared every ND in terms of efﬁcacy,
safety, posology (pharmacology??) and cost versus the
best pharmaceutical option for the same indication. By
means of a decision-making algorithm, ND were cate-
gorised as important, modest or null therapeutic improve-
ment. NDEC has external peer review. The NDEC
prepared an extensive evaluation and a reduced evalua-
tion. They were posted at the institution’s web and the
reduced evaluation was sent to GPs by post. The Speciﬁc
Intervention (SI) was activated when a ND was negatively
evaluated and the ND had a persistent high market share.
SI is an academic visit (face-to-face) between a pharma-
ceutical adviser and each GP, who is a constant prescriber
of the ND. We monitored the consumption of ND for two
years (2000–2001), using the same information from the
Madrid community (out of Catalonian) as a reference.
RESULTS: 85% of the 16 ND evaluated are in the “little
or null therapeutic improvement” category. The Cat-
alonian GPs had a lower ND utilisation rate than the
Madrid GPs (57% vs. 120%) and the reduction of the
utilisation tendency observed along 2001 was higher
(15% vs. 10%) in a biannual rate. On September 2001
the SI was activated for two drugs, ROFECOXIB 
and CELECOXIB (1,7% market share of pharmaceutical
sales). We interviewed 1000GPs and obtained a 35%
reduction in their prescribing. CONCLUSIONS: It’s pos-
sible to change the use of ND using evidence-based drug
information and a combined diffusion strategy of gener-
alized and one-on-one interventions.
HEALTH POLICY—Healthcare Expenditure Studies
PHP15
THE USE OF PATHOLOGY-RELATED
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OBJECTIVES: In order to allocate public resources on
health care more efﬁciently, lump sum based payment
systems are introduced in the Belgian hospital sector. This
study investigates the inﬂuence of pathology-related para-
meters on the consumption of medical imaging. A regres-
sion based method (ANCOVA) is used to deﬁne an
explanatory model for the expenditure on medical
imaging. METHODS: A representative sample of 30 hos-
pitals was withdrawn from the national data. This sample
contains 277.521 inpatient stays (19% of total), all of
which related to data on utilisation of resources as well
as data concerning the pathology. The pathology-related
